{
  "disease_name": "Primary hyperoxaluria",
  "orpha_code": "416",
  "drugs": [
    {
      "name": "Stiripentol",
      "substance_url": "/en/drug/substance/41778?name=416&mode=orpha&region=&status=all",
      "substance_id": "41778",
      "regulatory_url": "/en/drug/regulatory/589315?name=416&mode=orpha&region=",
      "regulatory_id": "589315",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "Stiripentol(Medicinal product                        - 26/06/2020)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "Stiripentol(Medicinal product                        - 26/06/2020)",
        "(Medicinal product                        - 26/06/2020)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/41778?name=416&mode=orpha&region=&status=all",
          "text": "Stiripentol",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589315?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Nedosiran",
      "substance_url": "/en/drug/substance/524602?name=416&mode=orpha&region=&status=all",
      "substance_id": "524602",
      "regulatory_url": "/en/drug/regulatory/528536?name=416&mode=orpha&region=",
      "regulatory_id": "528536",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "Nedosiran(Medicinal product                        - 31/07/2018)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "Nedosiran(Medicinal product                        - 31/07/2018)",
        "(Medicinal product                        - 31/07/2018)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/524602?name=416&mode=orpha&region=&status=all",
          "text": "Nedosiran",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/528536?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Bacillus subtilis oxalate decarboxylase",
      "substance_url": "/en/drug/substance/493796?name=416&mode=orpha&region=&status=all",
      "substance_id": "493796",
      "regulatory_url": "/en/drug/regulatory/494616?name=416&mode=orpha&region=",
      "regulatory_id": "494616",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "Bacillus subtilis oxalate decarboxylase(Medicinal product                        - 17/07/2017)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "Bacillus subtilis oxalate decarboxylase(Medicinal product                        - 17/07/2017)",
        "(Medicinal product                        - 17/07/2017)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/493796?name=416&mode=orpha&region=&status=all",
          "text": "Bacillus subtilis oxalate decarboxylase",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/494616?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
      "substance_url": "/en/drug/substance/458734?name=416&mode=orpha&region=&status=all",
      "substance_id": "458734",
      "regulatory_url": "/en/drug/regulatory/458735?name=416&mode=orpha&region=",
      "regulatory_id": "458735",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues(Medicinal product                        - 21/03/2016)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues(Medicinal product                        - 21/03/2016)",
        "(Medicinal product                        - 21/03/2016)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/458734?name=416&mode=orpha&region=&status=all",
          "text": "Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/458735?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid",
      "substance_url": "/en/drug/substance/628274?name=416&mode=orpha&region=&status=all",
      "substance_id": "628274",
      "regulatory_url": "/en/drug/regulatory/628275?name=416&mode=orpha&region=",
      "regulatory_id": "628275",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 14/01/2022)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 14/01/2022)",
        "(Medicinal product                        - 14/01/2022)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/628274?name=416&mode=orpha&region=&status=all",
          "text": "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/628275?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA",
      "substance_url": "/en/drug/substance/695311?name=416&mode=orpha&region=&status=all",
      "substance_id": "695311",
      "regulatory_url": "/en/drug/regulatory/695440?name=416&mode=orpha&region=",
      "regulatory_id": "695440",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA(Medicinal product                        - 02/02/2025)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA(Medicinal product                        - 02/02/2025)",
        "(Medicinal product                        - 02/02/2025)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/695311?name=416&mode=orpha&region=&status=all",
          "text": "Lipid nanoparticle encapsulating a messenger RNA for the CRISPR-based gene editor Cas12i2v2.1, and an HAO1- specific guide RNA",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/695440?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene",
      "substance_url": "/en/drug/substance/688334?name=416&mode=orpha&region=&status=all",
      "substance_id": "688334",
      "regulatory_url": "/en/drug/regulatory/688472?name=416&mode=orpha&region=",
      "regulatory_id": "688472",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene(Medicinal product                        - 20/09/2024)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene(Medicinal product                        - 20/09/2024)",
        "(Medicinal product                        - 20/09/2024)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/688334?name=416&mode=orpha&region=&status=all",
          "text": "Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a CRISPR RNA (crRNA) targeting the HAO1 gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/688472?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid",
      "substance_url": "/en/drug/substance/687138?name=416&mode=orpha&region=&status=all",
      "substance_id": "687138",
      "regulatory_url": "/en/drug/regulatory/687314?name=416&mode=orpha&region=",
      "regulatory_id": "687314",
      "orpha_substance_code": "ORPHA:416",
      "details": [
        "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid(Medicinal product                        - 21/08/2024)Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid(Medicinal product                        - 21/08/2024)",
        "(Medicinal product                        - 21/08/2024)",
        "Disease(s) concernedORPHA:416 Primary hyperoxaluria",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/687138?name=416&mode=orpha&region=&status=all",
          "text": "2-(2-(cyclopropylmethyl)-1-(3-fluoro-4-sulfamoylbenzyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)-6-methylpyrimidine-4-carboxylic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/416",
          "text": "ORPHA:416 Primary hyperoxaluria",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/687314?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Oxlumo",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/596200?name=416&mode=orpha&region=",
      "regulatory_id": "596200",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "Oxlumo(Tradename                        - 19/11/2020)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "Oxlumo(Tradename                        - 19/11/2020)",
        "(Tradename                        - 19/11/2020)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/596199?name=416&mode=orpha&region=&status=all",
          "text": "Oxlumo",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/596200?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Oxalobacter formigenes strain HC-1",
      "substance_url": "/en/drug/substance/75716?name=416&mode=orpha&region=&status=all",
      "substance_id": "75716",
      "regulatory_url": "/en/drug/regulatory/134032?name=416&mode=orpha&region=",
      "regulatory_id": "134032",
      "orpha_substance_code": "ORPHA:93599",
      "details": [
        "Oxalobacter formigenes strain HC-1(Medicinal product                        - 17/02/2006)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1ORPHA:93599 Primary hyperoxaluria type 2",
        "Oxalobacter formigenes strain HC-1(Medicinal product                        - 17/02/2006)",
        "(Medicinal product                        - 17/02/2006)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1ORPHA:93599 Primary hyperoxaluria type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/75716?name=416&mode=orpha&region=&status=all",
          "text": "Oxalobacter formigenes strain HC-1",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93599",
          "text": "ORPHA:93599 Primary hyperoxaluria type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/134032?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene",
      "substance_url": "/en/drug/substance/444886?name=416&mode=orpha&region=&status=all",
      "substance_id": "444886",
      "regulatory_url": "/en/drug/regulatory/444890?name=416&mode=orpha&region=",
      "regulatory_id": "444890",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene(Medicinal product                        - 28/07/2015)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene(Medicinal product                        - 28/07/2015)",
        "(Medicinal product                        - 28/07/2015)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/444886?name=416&mode=orpha&region=&status=all",
          "text": "Synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/444890?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene",
      "substance_url": "/en/drug/substance/299531?name=416&mode=orpha&region=&status=all",
      "substance_id": "299531",
      "regulatory_url": "/en/drug/regulatory/301092?name=416&mode=orpha&region=",
      "regulatory_id": "301092",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene(Medicinal product                        - 21/03/2012)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene(Medicinal product                        - 21/03/2012)",
        "(Medicinal product                        - 21/03/2012)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/299531?name=416&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate aminotransferase gene",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/301092?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "RIVFLOZA",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/697177?name=416&mode=orpha&region=",
      "regulatory_id": "697177",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "RIVFLOZA(Tradename                        - 27/03/2025)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "RIVFLOZA(Tradename                        - 27/03/2025)",
        "(Tradename                        - 27/03/2025)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/660417?name=416&mode=orpha&region=&status=all",
          "text": "RIVFLOZA",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/697177?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "RIVFLOZA",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/660486?name=416&mode=orpha&region=",
      "regulatory_id": "660486",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "RIVFLOZA(Tradename                        - 29/09/2023)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "RIVFLOZA(Tradename                        - 29/09/2023)",
        "(Tradename                        - 29/09/2023)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/660417?name=416&mode=orpha&region=&status=all",
          "text": "RIVFLOZA",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/660486?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Oxlumo",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/633622?name=416&mode=orpha&region=",
      "regulatory_id": "633622",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "Oxlumo(Tradename                        - 06/10/2022)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "Oxlumo(Tradename                        - 06/10/2022)",
        "(Tradename                        - 06/10/2022)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/596199?name=416&mode=orpha&region=&status=all",
          "text": "Oxlumo",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/633622?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Oxlumo",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/623117?name=416&mode=orpha&region=",
      "regulatory_id": "623117",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "Oxlumo(Tradename                        - 23/11/2020)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "Oxlumo(Tradename                        - 23/11/2020)",
        "(Tradename                        - 23/11/2020)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/596199?name=416&mode=orpha&region=&status=all",
          "text": "Oxlumo",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/623117?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid",
      "substance_url": "/en/drug/substance/643876?name=416&mode=orpha&region=&status=all",
      "substance_id": "643876",
      "regulatory_url": "/en/drug/regulatory/643877?name=416&mode=orpha&region=",
      "regulatory_id": "643877",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 08/06/2022)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid(Medicinal product                        - 08/06/2022)",
        "(Medicinal product                        - 08/06/2022)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/643876?name=416&mode=orpha&region=&status=all",
          "text": "5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/643877?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Glycolate oxidase inhibitor",
      "substance_url": "/en/drug/substance/651177?name=416&mode=orpha&region=&status=all",
      "substance_id": "651177",
      "regulatory_url": "/en/drug/regulatory/651178?name=416&mode=orpha&region=",
      "regulatory_id": "651178",
      "orpha_substance_code": "ORPHA:93598",
      "details": [
        "Glycolate oxidase inhibitor(Medicinal product                        - 10/09/2020)Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "Glycolate oxidase inhibitor(Medicinal product                        - 10/09/2020)",
        "(Medicinal product                        - 10/09/2020)",
        "Disease(s) concernedORPHA:93598 Primary hyperoxaluria type 1",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/651177?name=416&mode=orpha&region=&status=all",
          "text": "Glycolate oxidase inhibitor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/93598",
          "text": "ORPHA:93598 Primary hyperoxaluria type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/651178?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=416&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=416&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=416&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=416&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=416&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=416&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=416&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=416&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=416&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=416&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:01:48.271206",
  "run_number": 1,
  "total_drugs_found": 21,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Primary+hyperoxaluria&orphaCode=416&name=416&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Primary hyperoxaluria",
    "orphaCode": "416",
    "name": "416",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}